The purpose of a clinical trial is to determine the most effective and safest treatment for a disease. Clinical trials are a key step to translating research into new medicines that can provide better outcomes for patients. The performance of clinical trials is a vital component of U.S. Food and Drug Administration’s drug approval process, without which advances in therapeutics for celiac disease patients would not be possible. Finding people to participate in trials can take a long time, slowing down the process. This Clinical Trial Finder is intended to raise awareness and increase participation in celiac disease clinical trials to accelerate research into treatments and a cure.
Your search will show information that has been obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical trials of human participants with locations in all 50 States and in 196 countries.
Finding a Trial
To help you find clinical trials that may best suit your particular needs, please answer the questions below. The more questions you answer, the more specific the results will be. To see a greater number of studies in the results, remove any filter(s) and run the search again.
After reviewing your search results, if you are interested in learning more about a trial, identify the trial site nearest to your location and contact the site coordinator via the email or phone listed. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
-
Acute Abdomen in Adults- a Prospective Study on Emergency Department Admissions
This is a non-randomized, prospective, population-based, single-center study designed to evaluate conditions resulting emergency admission in patients with abdominal pain. Furthermore, we are interested in how many patients are discharged with "non-specific abdominal pain" but later readmitted and diagnosed with a specific diagnosis.
-
AN-PEP on Gluten Exposure in Celiacs
The AN-PEP, an Aspergillus niger derived endopeptidase, has been developed aiming to produce a complete luminal detoxification of gluten. If AN-PEP is able to produce a complete luminal digestion of gluten in the context of the real life of celiac disease (CeD) patients is unknown. Hypothetically, AN-PEP effect could be detected by the reduction in the excretion of GIP in stool and urine. The objective of this study is to establish the effect of the daily administration of AN-PEP compared to placebo on GIP excretion in an interventional, prospective, randomized, comparative, double-blind study in conditions mimicking the real-life...
-
A Pilot Study to Explore the Role of Gut Flora in Celiac Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Celiac Disease.
-
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
-
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
-
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
-
A Study to Assess the Safety of TPM502 in Adults With Celiac Disease
The goal of this clinical trial is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease. The main questions it aims to answer are: - if TPM502 is safe and well tolerated - if TPM502 can induce modifications in parameters indicating that it may induce tolerance to gluten Participants will: - undergo 1-day gluten challenge during screening and after administration of TPM502 or placebo. - receive 2 infusions of TPM502 or placebo, 2 weeks apart
-
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
-
Background of Different Phenotypes of Coeliac Disease
The main purpose of this study is to investigate genetic, serological, immunological and microbiata diversities between different coeliac disease phenotypes and to discover applicable prognostic markers for specific phenotypes.
-
Bio-markers of Not-celiac Wheat Sensitivity
The aim of the investigators' study is to evaluate biochemical, immunological and histological characteristics of patients affected with the so-called "gluten (or wheat) sensitivity" who suffers from irritable bowel syndrome (IBS)-like symptoms. As it is not known what component of the cereals causes the symptoms in so called "gluten-sensitive" patients, the investigators prefer to speak of "not-celiac wheat sensitivity" (NCWS). NCWS patients may be defined as ones, neither celiac or allergic to wheat, who develop symptoms following wheat consumption, that improved on wheat/gluten free diet (GFD). For our research, we will...
Opt-in to stay up-to-date on the latest news.
Yes, I want to advance research No, I'd prefer not toDon't show me this again